Zura Bio Ltd. Reports Financial Results for 2025, Highlights Strategic Developments
Zura Bio Ltd., a clinical-stage biotechnology company, reported a net loss of $68.7 million for the fiscal year ended December 31, 2025, compared to a net loss of $52.4 million for the previous year. The increased loss was primarily attributed to higher research and development expenses as the company advanced its Phase 2 clinical trials. Research and development expenses totaled $42.1 million in 2025, a significant increase from $24.4 million in 2024, driven by costs associated with CRO fees, compensation, and a one-time milestone payment. General and administrative expenses also saw a slight increase, rising to $33.2 million from $30.8 million in the prior year, mainly due to higher professional fees.
The company's financial position remains relatively stable, with cash and cash equivalents totaling $109.4 million as of December 31, 2025, compared to $176.5 million at the end of 2024. This decrease reflects the ongoing investment in clinical trials and operational activities. Zura Bio has no products approved for commercial sale and has not generated any revenue to date. The company is dependent on raising additional capital to fund its operations and advance its product candidates through clinical development.
Operationally, Zura Bio is focused on advancing its three clinical-stage product candidates: tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). The company is currently conducting two global Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) and diffuse cutaneous systemic sclerosis (dcSSc). In January 2026, the company expanded the planned enrollment for the TibuSHIELD trial in HS from approximately 180 participants to approximately 225 participants. Topline results from the 16-week double-blind portion of the TibuSHIELD trial are expected in the fourth quarter of 2026, while topline results from the 24-week double-blind portion of the TibuSURE trial in dcSSc are expected in the first half of 2027.
In December 2025, Zura Bio entered into a letter agreement with Athanor Capital, issuing 8,657,402 Class A Ordinary Shares and agreeing to a one-time milestone payment of $25.0 million upon certain events, as well as a royalty of 2% of net sales for products subject to a royalty payment under the 2023 Lilly License. Concurrently, the company terminated letter agreements with Stone Peach Properties and BAFFX17, settling related obligations. The company anticipates that its existing cash and cash equivalents will be sufficient to fund operations through at least the end of 2028.
About Zura Bio Ltd
Zura Bio Limited is a clinical-stage biopharmaceutical company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory diseases. Its pipeline includes candidates targeting cytokines like IL-17, BAFF, IL-7, and IL-33, with potential to address unmet medical needs. The company leverages licensed technologies, collaborates with major pharma partners, and advances therapies through clinical trials aimed at broad immune modulation.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.